Journals / Mersin Üniversitesi Sağlık Bilimleri Dergisi / 2019 / Cilt: 12 - Sayı: 1

The clinical effects of genetic structure, estrogen, and toxic agents on Raynaud’s Phenomenon

Raynaud Fenomeni üzerine genetik yapı, östrojen ve toksik ajanların klinik etkileri

Pages
143–149
Publication Date
2019-04-28
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

As a result, although many factors have been described causing this disease, further research is needed to elucidate the molecular mechanisms underlying the onset and progression of RP.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Raynaud’s phenomenon (RP) is characterized by cold-induced vasoconstriction.
📊
Key Findings & Data:This enhanced vasoconstriction is achieved by a reflex response to cooling through the sympathetic nervous system and by local activation of Alpha2C (α2C) adrenoreceptors.
💡
Conclusion & Impact:As a result, although many factors have been described causing this disease, further research is needed to elucidate the molecular mechanisms underlying the onset and progression of RP.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Raynaud fenomeni · vazospazm · Alfa2(α2) adrenoreseptörler

Abstract

Raynaud’s phenomenon (RP) is characterized by cold-induced vasoconstriction. This enhanced vasoconstriction is achieved by a reflex response to cooling through the sympathetic nervous system and by local activation of Alpha2C (α2C) adrenoreceptors. This disease is clinically classified as primary and secondary. Primary RP is idiopathic and is the most common form of the disease. Secondary RP may be associated with diseases such as autoimmune diseases or cancer, and smoking or the use of certain medications may also be cause. Affected individuals suffer from vasospastic attacks associated with classical three colour changes (paleness, cyanosis, and hyperemia), often triggered by cold and/or stress. The data from the epidemiological studies revealed interesting findings related to the prevalence of RP. It was determined that women with the same age had a significantly higher incidence than men. In this review, the effects of oestrogen, genetic structure and chemical agents on RP were discussed. As a result, although many factors have been described causing this disease, further research is needed to elucidate the molecular mechanisms underlying the onset and progression of RP.

Özet

Raynaud Fenomeni (RF) soğuk kaynaklı vazokonstrüksiyonla karakterize bir hastalıktır. Bu güçlendirilmiş vazokonstrüksiyon, sempatik sinir sistemi yoluyla soğumaya karşı bir refleks cevabı ve Alfa2C (α2C) adrenoreseptörlerinin lokal aktivasyonu ile gerçekleşmektedir. Bu hastalık klinik olarak primer ve sekonder olarak sınıflandırılmaktadır. Primer RF idiyopatiktir ve hastalığın en yaygın şeklidir. Sekonder RF, otoimmün veya kanser gibi hastalıklara eşlik edebileceği gibi, sigara içimi ya da bazı ilaçların kullanımı da sebebiyet verebilmektedir. Etkilenen bireyler, soğuk ve stresin tetiklemesiyle birlikte, genellikle el parmaklarında, klasik üç renk değişikliğiyle (solukluk, siyanoz ve hiperemi) ilişkili olan vazospastik ataklardan muzdarip olmaktadırlar. Epidemiyolojik çalışmalardan elde edilen veriler, RF prevalansı ile ilgili ilginç bulgular ortaya koymuştur. Yaşları aynı olan kadınların, erkeklere göre anlamlı olarak daha yüksek bir insidansa sahip olduğu belirlenmiştir. Bu derlemede, östrojenin, genetik yapının ve kimyasal ajanların RF üzerine olan etkileri tartışılmıştır. Sonuç olarak, bu hastalığa neden olan birçok faktör açıklanmasına rağmen, RF'nin başlangıcının ve ilerlemesinin altında yatan moleküler mekanizmaların aydınlatılması için daha fazla araştırmaya gereksinim duyulmaktadır.

🔖

Cite This Article

AKKAPULU, M., YALIN, A. E. (2019). The clinical effects of genetic structure, estrogen, and toxic agents on Raynaud’s Phenomenon. Mersin Üniversitesi Sağlık Bilimleri Dergisi, Cilt: 12 - Sayı: 1, 143–149. https://ajindex.com/articles/92820

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (18)

  1. Charkoudian N. Mechanisms and modifiers of reflex induced cutaneous vasodilation and vasoconstriction in humans. J. Appl. Physiol. 2010
  2. 109(1985):1221–1228. 2.Wigley FM, Flavahan NA.Raynaud’s phenomenon.N.Engl.J.Med. 2016
  3. 556–565. 3.Herrick AL. The pathogenesis, diagnosis and treatment of Raynaud phenomenon. Nat. Rev. Rheumatol. 2012
  4. 469–479. 4.Block JA, Sequeira W. Raynaud’s phenomenon. Lancet 2001
  5. 2042–2048. 5. Roustit M, Khouri C, Blaise S, Villier C, Carpentier P, Cracowski JL. Pharmacology of Raynaud’s phenomenon. Therapie 2014
  6. 115–128. 6. Prete M, Fatone MC, Favoino E, Perosa F. (2014). Raynaud’s phenomenon: from molecular pathogenesis to therapy. Autoimmun. Rev. 2014
  7. 655–667. 7. Black CM. Systemic sclerosis ‘state of the art’ 1995. Scand. J. Rheumatol. 1995
  8. 194–196. 8. Garner R, Kumari R, Lanyon P, Doherty M, Zhang W. Prevalence, risk factors and associations of primary Raynaud’s phenomenon: systematic review and meta-analysis of observational studies. BMJ 2015
  9. Open 5: e006389. 9. Maverakis E, Patel F, Kronenberg DG, Chung L, Fiorentino D, Allanore Y, et al. (2014). International consensus criteria for the diagnosis of Raynaud’s phenomenon. J. Autoimmun. 2014
  10. 60–65. 10. Fardoun MM, Nassif J, Issa K, Baydoun E, Eid AH. Raynaud’s Phenomenon: A brief review of the underlying mechanisms. Front. Pharmacol. 2016
  11. Greenstein D, Jeffcote N, Ilsley D, Kester RC. The menstrual cycle and Raynaud’s phenomenon. Angiology. 1996
  12. 427–436. 12. Wigley FM. Clinical practice. Raynaud’s phenomenon. N. Engl. J. Med. 2002
  13. 1001–1008. 13. Easter M J, Marshall JM. Contribution of prostanoids to endothelium-dependent vasodilatation in the digital circulation of women with primary Raynaud’s disease. Clin. Sci. (Lond). 2005
  14. 45–54. 14. Guimaraes S, Moura D. Vascular adrenoceptors: an update. Pharmacol. Rev. 2001
  15. 319–356. 15. Ahles A, Engelhardt S. Polymorphic variants of adrenoceptors: pharmacology, physiology, and role in disease. Pharmacol. Rev. 2014
  16. 598–637. 16. McCance KL, Huether SE. Pathophysiology: The Biologic Basis for Disease in Adults and Children. Amsterdam: Elsevier. 2013. 17. Polonia JJ., Paiva MQ, Guimaraes S. Pharmacological characterization of postsynaptic alpha-adrenoceptor subtypes in five different dog arteries in-vitro. J. Pharm. Pharmacol. 1985
  17. 205–208. 18. Johnson JM, Kellogg DLJr. Local thermal control of the human cutaneous circulation. J. Appl. Physiol. 2010
  18. 1229–1238. 19. Freedman RR, Sabharw